mRNA |
tivozanib |
CTRPv2 |
pan-cancer |
AAC |
-0.079 |
0.03 |
mRNA |
BRD-K99584050 |
CTRPv2 |
pan-cancer |
AAC |
0.11 |
0.04 |
mRNA |
pac-1 |
CTRPv2 |
pan-cancer |
AAC |
0.074 |
0.04 |
mRNA |
PF-184 |
CTRPv2 |
pan-cancer |
AAC |
0.068 |
0.04 |
mRNA |
CHEMBL1222381 |
CTRPv2 |
pan-cancer |
AAC |
0.067 |
0.04 |
mRNA |
BRD-K51831558 |
CTRPv2 |
pan-cancer |
AAC |
0.11 |
0.04 |
mRNA |
Doxorubicin |
CTRPv2 |
pan-cancer |
AAC |
0.061 |
0.04 |
mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.069 |
0.04 |
mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.06 |
0.04 |
mRNA |
UNC0638:navitoclax (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.073 |
0.04 |